Solid tumours cannot grow beyond 1–2 mm in diameter without neovascularisation — the formation of new blood vessels supplying oxygen and nutrients. The 'angiogenic switch' — when pro-angiogenic signals overcome anti-angiogenic restraints — is a critical early step in tumour progression. Folkman's seminal hypothesis (1971) that tumours require angiogenesis has been validated by decades of mechanistic research culminating in anti-VEGF therapies that are now standard of care in colorectal, lung, cervical, ovarian, and renal carcinomas.
Tumour hypoxia — inevitable as rapidly dividing cells outgrow their oxygen supply — stabilises HIF-1α by inhibiting the PHD enzymes that normally tag it for VHL-mediated proteasomal degradation. Stabilised HIF-1α drives VEGFA transcription from its HRE-containing promoter. Secreted VEGFA165 binds VEGFR2 on adjacent endothelial cells, activating PLCγ/PKC (endothelial proliferation), PI3K/AKT (survival), and SRC/FAK (permeability and migration) cascades. Together these drive tip cell specification, stalk cell proliferation, and lumen formation — creating new vascular conduits that relieve hypoxia and supply nutrients for further tumour growth.
Tumour hypoxia — inevitable as rapidly dividing cells outgrow their oxygen supply — stabilises HIF-1α by inhibiting the PHD enzymes that normally tag it for VHL-mediated proteasomal degradation. Stabilised HIF-1α drives VEGFA transcription from its HRE-containing promoter. Secreted VEGFA165 binds VEGFR2 on adjacent endothelial cells, activating PLCγ/PKC (endothelial proliferation), PI3K/AKT (survival), and SRC/FAK (permeability and migration) cascades. Together these drive tip cell specification, stalk cell proliferation, and lumen formation — creating new vascular conduits that relieve hypoxia and supply nutrients for further tumour growth.
Rapidly dividing tumour cells create hypoxic pockets (<1% O2). Hypoxia inhibits PHD enzymes (which require O2 for catalysis), preventing Pro402/564 hydroxylation of HIF-1α. Without hydroxylation, VHL cannot ubiquitinate HIF-1α — it stabilises, accumulates, and translocates to the nucleus.
Secreted VEGFA165 binds VEGFR2 (KDR) extracellular domains, inducing receptor homodimerisation and autophosphorylation at Tyr1054/1059 (activation loop) and Tyr1175 (PLCγ/Shb docking). VEGFR1 (FLT1) acts primarily as a decoy to fine-tune VEGFA bioavailability.
High VEGFA gradients preferentially activate DLL4/Notch signalling in leading endothelial 'tip cells', which extend filopodia guided by VEGFA gradients. DLL4-Notch in tip cells suppresses VEGFR2 expression in neighbouring 'stalk cells', enforcing tip/stalk hierarchy to ensure directional and controlled vessel sprouting.
VEGFR2-mediated SRC activation loosens VE-cadherin adherens junctions (vascular permeability), enabling endothelial cell migration. Stalk cells proliferate to extend the sprout behind the tip. Lumen formation occurs through cell hollowing or cord hollowing mechanisms. PDGFB secreted by endothelial cells recruits pericytes for vessel stabilisation.
Biallelic VHL loss in clear cell renal carcinoma prevents PHD-mediated HIF-α hydroxylation even in normoxia. HIF-1α and HIF-2α are constitutively active regardless of oxygen, driving maximal VEGFA, PDGFB, and CXCR4 expression. This VHL-loss phenotype makes ccRCC exquisitely sensitive to anti-VEGF and VEGFR TKI therapy.
Angiogenesis is a near-universal requirement for solid tumour growth beyond micrometastasis. Tumour vasculature is structurally aberrant — tortuous, leaky, poorly perfused — creating the hypoxia that drives further VEGF production (positive feedback). Bevacizumab-containing regimens improve overall survival in colorectal cancer (bevacizumab + FOLFOX/FOLFIRI) and progression-free survival in ovarian cancer, NSCLC, and cervical cancer.
Bevacizumab (anti-VEGFA monoclonal antibody) normalises tumour vasculature, improving drug delivery and reducing oedema (particularly in GBM). VEGFR TKIs (sunitinib, pazopanib, axitinib, cabozantinib) target intracellular VEGFR signalling and are approved for RCC, HCC, and thyroid cancer. Belzutifan (HIF-2α inhibitor) is approved for VHL disease-associated tumours. Resistance mechanisms include FGF2, PDGF, angiopoietin-2 as VEGF-independent angiogenic signals.
What is the angiogenic switch?
The angiogenic switch is the transition from an avascular to a vascularised tumour state, defined by an imbalance between pro-angiogenic (VEGFA, FGF2, angiopoietins) and anti-angiogenic (thrombospondin-1, endostatin, angiostatin) signals tipping in favour of neovascularisation. It typically occurs at tumour sizes of 1–2 mm and marks a key transition in tumour progression toward metastatic competence.
Why does anti-VEGF therapy fail over time?
Resistance to anti-VEGF therapy arises through multiple mechanisms: upregulation of alternative angiogenic factors (FGF2, PDGF, angiopoietin-1/2, EGF) that drive angiogenesis independent of VEGFA; vessel co-option (tumours grow along pre-existing vessels without neoangiogenesis); increased pericyte coverage making vessels less VEGFA-dependent; and selection of hypoxia-tolerant tumour cell populations.
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
Cell Cycle Regulation Genes
Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regula…
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway is the most frequently activated oncogenic signalling axis in human cancer, altered in over 70…
Content is based on peer-reviewed scientific literature including data from NCBI, UniProt, PubMed, and TCGA. Gene links reference curated molecular biology databases. For educational purposes only; does not constitute clinical advice.